Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108591

SCHEMBL1108591

SCHEMBL1108591

CNc1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.52
▸ MAOB P27338 1/20 0.52
▸ CA2 P00918 1/20 0.49
▸ MMP2 P08253 1/20 0.49
▸ MMP9 P14780 1/20 0.49
▸ MMP8 P22894 1/20 0.49
▸ MMP14 P50281 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CA14 Q9ULX7 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PGR P06401 1/20 0.46
▸ SCN9A Q15858 10/20 0.45
▸ KCNH2 Q12809 8/20 0.45
▸ SCN5A Q14524 5/20 0.45
▸ HTR2A P28223 3/20 0.44
▸ SLC6A4 P31645 3/20 0.44
▸ PNLIP P16233 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761659 0.88 TSHR (0.48) CA2ALDH1A1L3MBTL1PGR
SCHEMBL15339364 0.88 TSHR (0.48) CA2ALDH1A1L3MBTL1PGR
SCHEMBL228690 0.85 — —
SCHEMBL29113884 0.84 MAPT (0.54) CA2CA9CA14ALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL10343601 0.83 ALDH1A1 (0.48) CA2CA9CA14ALDH1A1
SCHEMBL21340750 0.83 MAOA (0.48) MAOAMAOBCA2MMP2MMP9
SCHEMBL12883380 0.81 LMNA (0.47) MAOAMAOBALDH1A1PGRSCN9A
SCHEMBL457634 0.80 MAOA (0.74) MAOAMAOBCA2MMP2MMP9
SCHEMBL9242729 0.80 MAOA (0.74) MAOAMAOBCA2MMP2MMP9
SCHEMBL24438615 0.79 PNLIP (0.56) KCNH2HTR2ASLC6A4PNLIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 — — US disclosed
WO-2022103572-A1 COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-05-19 — — WO disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 — — EP disclosed
CN-106879256-B 2-amino-benzimidazole derivatives and their use as inhibitors of 5-lipoxygenase and/or prostaglandin e synthase 韩国巴斯德研究所 2021-08-03 — — CN disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 — — US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 — — EP disclosed
WO-2019170088-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF 北京赛特明强医药科技有限公司 2019-09-12 — — WO disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 — — WO disclosed
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-08-04 — — US disclosed
CN-104718213-A 5, 5-heteroaromatic anti-infective compounds UNIV NOTRE DAME 2015-06-17 — — CN disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 — — US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MAOA 282/4885MAOB 163/4885CA2 139/4885
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS AARS1, EPRS1, EEF1G MAOA 1092/4885MAOB 1246/4885CA2 4809/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MAOA 282/4885MAOB 163/4885CA2 139/4885
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 MAOA 1220/4885MAOB 975/4885CA2 1170/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 MAOA 201/4885MAOB 143/4885CA2 199/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 MAOA 1220/4885MAOB 975/4885CA2 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.